Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News...
PharmaCom BioVet, Inc. Announces Cancer Care Centers to Incorporate
Significant Benefits of Lymphoma Blood Tests for Canine Cancer Treatments
RALEIGH, NC, Nov 18, 2008 (MARKET WIRE via COMTEX) -- PharmaCom BioVet, Inc.
(PINKSHEETS: PHMB). PharmaCom BioVet, Inc. is pleased to announce the
incorporation of PetScreen LTD into their companion animal treatment centers and
the benefits of PetScreen, LTD's Lymphoma Blood Testing in the treatment of
canine cancer treatments.
PharmaCom BioVet, Inc. President and CEO, Gary Berthold has confirmed plans to
promote and incorporate current Lymphoma Blood Testing programs developed by
PetScreen LTD of Nottingham, UK into its new canine cancer treatments centers.
In a recent letter from PetScreen LTD's CEO, Dr. Kevin Slater, the collaboration
between the two companies is seen as an important step forward in improving
cancer diagnosis and treatment for companion animals. "Lymphoma is one of the
most common forms of cancer in dogs and accounts for a significant percentage of
cancer deaths," Berthold noted. "The Canine Lymphoma Blood Test procedure
pioneered by PetScreen will provide our treatment centers, and veterinarians
everywhere, with a very simple means of testing for the disease."
"The benefits are wide ranging and will aid in the screening, diagnosis and
monitoring of lymphoma treatments programs," Berthold continued. "This process
is highly valuable in tracking the efficacy of various levels of treatment as
well as the overall results from radio pharmaceutical usage. Of equal importance
is its ability to provide vital information once a patient's cancer has gone
into remission. It will allow us to better determine how the treatment worked
and, consequently, how to replicate those results," he added.
"Our recent collaboration with PetScreen LTD further enables us to provide
effective, state-of-the-art canine cancer treatment programs within our
treatment centers," offered Berthold. "Our goal is to help lead the way towards
the highest achievements possible in cancer care for companion animals. One of
the key factors in attaining this goal is the formation of synergistic
relationships with professionals around the country and the world. With each
collaboration, we are working to assemble the best minds in the field of cancer
research and veterinary oncology. Combined with leading edge technologies and
procedures, such as Lymphoma Blood Testing, our hope is to accelerate the
progress towards optimum treatment results and an eventual cure," he concluded.
PetScreen LTD, founded by Dr. Slater and Board Chairman, Professor Graeme
Radcliffe, was established to provide veterinarians with improved testing
methodologies in order to help them make better diagnostic and treatment
decisions for companion animals with cancer. The company features a
comprehensive range of services and a growing cooperative network of industry
professionals.
PharmaCom BioVet, Inc. is the inspiration of Gary and Sharon Berthold of
Raleigh, NC. Avid Siberian Husky breeders and life-long dog lovers, the
Berthold's were driven to establish the company following the loss of two of
their most precious Siberian Huskies to cancer. While researching medical
remedies, they discovered a growing nationwide demand for canine cancer care
along with an astonishing lack of effective treatment options. To address these
realities, they formed PharmaCom BioVet, Inc. to establish canine cancer
treatment centers around the country. These facilities will link the brightest
veterinary leaders with the latest oncology technologies to offer the most
advanced cancer treatment programs available.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. is dedicated to advancing the veterinary care industry
for companion animals by establishing state-of-the-art treatment centers for
lymphoma and other forms of cancer throughout the country. The purpose of these
centers is to help prolong the quality of life for companion animals with cancer
and pursue the potential for complete cure. These centers will also operate
under the philosophy of providing a compassionate care environment for both
companion animal patients and their owners. For more information, please visit
our website www.PharmaComBioVet.com.
About PetScreen, LTD:
PetScreen LTD. is headquartered and operates laboratories in Nottingham,
England. Its purpose is to develop and apply new technologies directed towards
improving cancer diagnosis and treatment in dogs and other companion animals.
Their facilities offer services such as Canine Lymphoma Blood Tests, which
provide veterinarians with a simple means of screening, diagnosis and monitoring
treatment of dogs with lymphoma. Their DCA program (Directed Chemotherapy Assay)
helps in determining the most effective chemotherapy treatment for each
individual canine cancer patient. From their UK location, they have developed a
network of national and international collaborators to provide services and
support to the veterinary cancer patient. For more information, please visit the
website at www.pet-screen.com.
About IsoTherapeutics Group, LLC:
The mission of IsoTherapeutics Group, LLC is to develop novel diagnostic and
therapeutic agents for the treatment of severe diseases. ITG both develops their
own technologies as well as partners with other companies to help develop
pharmaceuticals. Of special interest are radiopharmaceuticals for oncology. In
house expertise includes synthetic organic chemistry, chelation chemistry,
radiochemistry, diagnostic and therapeutic isotopes, conjugation chemistry,
pharmacokinetics, and small animal research models. For more information, please
visit our website www.isotherapeutics.com.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995: This press release contains forward-looking statements that are subject to
risk and uncertainties, including, but not limited to, the impact of competitive
products, product demand, market acceptance risks, fluctuations in operating
results, political risk and other risks detailed from time to time in PharmaCom
BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks
could cause PharmaCom BioVet, Inc.'s actual results to differ materially from
those expressed in any forward-looking statements made by, or on behalf of,
PharmaCom BioVet, Inc.
Contact:
Market Ideas, Inc.
877-295-3981 ext. 2
info@marketideasinc.com
SOURCE: PharmaCom BioVet, Inc.
CONTACT: mailto:info@marketideasinc.com
Copyright 2008 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Alternative
Medical and Healthcare:Health and Nutrition
Pharmaceuticals and Biotech:Drugs
Medical and Healthcare:Surgery and Treatments
Medical and Healthcare:Medical Devices
I like their new site MUCH better, I just wish it had content. Why do people go to all the trouble to make a site look professional and then forget the easy part, the text?
Stephen
News...
PharmaCom BioVet, Inc. Announces Corporate Vision to Research, Treat and
Compassionately Care for Companion Animals Afflicted With Cancer
RALEIGH, NC, Oct 07, 2008 (MARKET WIRE via COMTEX) -- PharmaCom BioVet, Inc.
(PINKSHEETS: PHMB) is pleased to announce their corporate vision to research,
treat and compassionately care for companion animals afflicted with cancer.
PharmaCom BioVet, Inc. is dedicated to advancing the medical care industry for
companion animals by establishing state-of-the-art treatment centers for
lymphoma and other forms of cancer throughout the country. The company's focus
is on furthering cancer research, treatment and care for companion animals.
Their primary goals include creating compassionate care facilities to treat
animals afflicted with cancer and to find products in conjunction with
procedures that will eradicate cancer in companion animals.
"Our ultimate goal is to work towards a day when we can eradicate cancer in
companion animals as we utilize our personal and professional relationships to
create a think tank of the brightest minds in the veterinary and university
fields to advance research and technology, all while focusing on compassionate
care," said Gary S. Berthold, Founder and CEO of PharmaCom BioVet.
With 75 million dogs in the United State alone, Americans spend $9.8 Billion a
year on veterinary services. Cancer is the number one cause of death in dogs,
with one out of every three dogs being diagnosed with cancer and 50% of those
dogs will succumb to their illness.
In response to demand and the current lack of adequate cancer treatment options
and facilities for animal lovers whose pets are suffering from cancer, PharmaCom
BioVet intends to open a network of companion animal cancer care centers
throughout North America.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. is dedicated to advancing the medical care industry for
companion animals by establishing state-of-the-art treatment centers for
lymphoma and other forms of cancer throughout the country. The purpose of these
centers is to help prolong the quality of life for companion animals with cancer
and pursue the potential for complete cure. These centers will also operate
under the philosophy of providing a compassionate care environment for both
companion animal patients and their owners. For more information, please visit
our website www.PharmaComBioVet.com.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995: This press release contains forward-looking statements that are subject to
risk and uncertainties, including, but not limited to, the impact of competitive
products, product demand, market acceptance risks, fluctuations in operating
results, political risk and other risks detailed from time to time in PharmaCom
BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks
could cause PharmaCom BioVet, Inc.'s actual results to differ materially from
those expressed in any forward-looking statements made by, or on behalf of,
PharmaCom BioVet, Inc.
Contact:
Market Ideas, Inc.
877-295-3981 ext. 2
info@marketideasinc.com
SOURCE: PharmaCom BioVet, Inc.
CONTACT: mailto:info@marketideasinc.com
Copyright 2008 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Lifestyle and Leisure:Family
Lifestyle and Leisure:Home and Garden
Lifestyle and Leisure:Women's Interest
Medical and Healthcare:Surgery and Treatments
Medical and Healthcare:Health and Nutrition
Medical and Healthcare:Healthcare
Medical and Healthcare:Facilities and Providers
Upside activity today.
As per their last PR:
"With this in mind, PharmaCom BioVet Inc. has established and incorporated working relationships and partnerships with some of the world's top Veterinary Oncologists and Veterinary cancer Researchers to enable PharmaCom BioVet to bring innovative new treatment procedures to the companion animal healthcare market."
I thought we would have gotten a PR concerning the split?
Who's your broker and what symbol do you see it in? I'm with Scottrade and see nothing.
Where do you see that form?
I wonder if we are seeing a slowing in buying today due to broker restrictions. I know that I can no longer buy this stock unless I call my broker (Scottrade). They do this to penny stocks every once in a while due to the volume and swing in price.
Hmmm....July 31st. If ABVG can meet this deadline than we'll see plenty of movement.
I as well.
So far so good, I'm surprised that there weren't more posts today. Good volume, good looking bid/ask.
Did anyone see the trade that put us to .0033? I thought we had closed lower, must have been an after hours trade?
Are you saying one of these is forthcoming?
http://www.georeferenceonline.com/NI%2043-101.htm
Not I, but I did grab a few more.
Wow, big buy; 2.5 milltion shares. Wish I had that many at this price
Correct you are, just sitting on the sidelines and watching/waiting.
I for one am hoping this is the case. Sounds logical.
Done. But not by me, I'm out of funds for the day.
I wish mine were that low too, I'm at .013 as an average now.
More added. I only got a third of what I wanted at .004 though before the bid/ask moved up.
Ditto, my feelings as well. I'm holding and adding.
Another 200...
200 I need shares badly,but do not take the stock down.
Thats one of the bigger spreads I've seen on this stock after hours...
.004 x .0175
Way to be an optimist!
Who knows if this is true, but 500 means to gap the stock, it appears (3x) that is what is happening. Of course the 500 buy was at ASK and they are gapping down...
MARKET MAKER SIGNALS
Penny traders believe that Market Makers (MM) will "signal" moves in advance buy using small amounts of buys or sells as "signals". The "signals" are such a small amount of shares (worth no more than 5 or 10 dollars) that no trader would have paid a commission that costs more than the amount of shares bought. The "signals" are from one MM to another.
100 I need shares.
200 I need shares badly,but do not take the stock down.
300 Take the price down so I can load shares
400 Keep trading it sideways.
500 Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.
Remeber this is a theory put forth by a lot of penny stock traders. This is not a guaranteed trading method so please use common sense and purchase stocks only after researching your investment thoroughly.
lol, at the last minute a paint job to .007
What is cie?
zzub, do you still have your buy order in at .0065?
"With 51.61 million shares outstanding and 129,000 shares declared short as of March 2008, there is a failure to deliver in shares of ABVG"
Oooh. Scary. 129,000 shares? $800 worth? Why would this even make the list?
I noticed that as well. I have no problem holding if I continue to see these kind of patterns.
Still, a lot of accumulation today with over 2 million shares traded and only one large (100k) sell at the bid.
Some good chunks going today, two at 500k, another at 200k. I wish Dan would update us as to what is happening behind the scenes...
Does anyone know why we had a quiet day today and a large volume of buys today? Friday vs. Monday? Rumer of a PR?
Much better volume today, close to 2 million shares. Not nearly where we need to be but a lot of these were buys.
Not too surprising, probably someone who bought that .004 that is tired of waiting.
It is hard to get anything below .008, I tried all day yesterday (to get .0075) and could only get 30k shares. I was able to pickup about 400k at 8 but with no move in the ask.
I was in the CC and heard that the relationship between the two of them was ongoing but I never heard anyone mention that Dale was being paid in stock rather than in cash. I should have been more clear, this was the main fact I was pointing out.
Hmm...Looks like our Dale Baeten at Midwest Stock Consulting has been paid? It used to say that he was receiving $2k a month for services, now it says he is/has received 1,500,000 Free Trading Shares from ABVG Inc.
Dan mentioned that he had not yet been paid the 2k a month (which supposably could have been paid at a later date), maybe the agreement has now changed? I have received emails from Dale indicating that he is actively working for Dan.
It appears the webpage is slowly being updated today, most notably the latest news on the front page and at http://www.abvgoldinc.com/news.php
It also appears that more eyes are watching future developments; stockwire.com, otcstockexchange.com, growthstockanalyst.com, otcpicks.com, Pinnacle Digest...quite a list!
Be patient...much more to come. On that note, where is littleredbarn?